|
DUBLIN(BUSINESS WIRE)
Research and Markets(http://www.researchandmarkets.com/research/5417ca/portugal-pharmaceu)
has announced the addition of the "Portugal
Pharmaceuticals and Healthcare Report Q4 2009" report to their
offering.
Portugal Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Portugal's
pharmaceuticals and healthcare industry.
BMI calculates that pharmaceutical sales in Portugal reached EUR3.61bn
(US$5.31bn) in 2008. We calculate that the sales of prescription and
over-the-counter (OTC) medicines will reach a value of EUR0.302bn by
2013, equating to a constant annual growth rate (CAGR) of 2.79% in local
currency terms. We note that as a result of the weakening euro, drug
market expenditure in US dollar terms will experience a decline 2009,
2010, 2011 and 2012, before reaching a value of US$5.11bn by 2013,
equating to a CAGR of -0.77%.
In BMI's Q409 Business Environment Ratings table for Western Europe,
Portugal scores 59.7, down from its Q309 score of 62.6. In regional
terms, Portugal is rated 8th of the 9 countries in the Western Europe
matrix, above Italy and below Belgium. In global terms, Portugal is
positioned in 15th place (down one place compared to the previous
quarter), above the Czech Republic and the United Arab Emirates (UAE)
and below Belgium and the Netherlands, out of the 71 markets surveyed by
BMI.
The government plays a significant role in the healthcare. Public sector
expenditure accounted for 70.5% of spending in 2008. However, an
increase in the uptake of private insurance will result in this number
falling to 69% over the next five years. In July 2009, new data showed
that approximately a third of the population (3mn out of 10.7mn) are
turning to the private sector for treatment, a figure that has tripled
over the past 30 years. The private healthcare sector in Portugal is
worth approximately US$994mn- US$1.14bn annually and in 2008, the Mello
Group's private healthcare scheme earned revenues of US$397mn, Banco
Esperito Santo's private healthcare plan earned revenues of US$119mn and
stateowned Caixa Geral de Depositos' healthcare scheme earned US$89mn.
In August 2009, Portugal's National Health Plan said that the
consumption of sedatives and antidepressants in Portugal is on the rise.
Consumption of anxiolytics, soporifics, sedatives and antidepressants
increased by 32% between 2002 and 2008. In Portugal in 2002, 115.6 doses
of sedatives and antidepressants were consumed per 1,000 inhabitants per
day, and by 2008 this figure had increased to 152.1 doses per 1,000
inhabitants per day. Portugal is therefore way above the European
average for consumption of this type of medicine, which stands at 41.3
doses per 1,000 people per day. The National Health Plan aims to reduce
the consumption of sedative and antidepressant medicines to 92.5 doses
per 1,000 inhabitants per day by 2010.
In September 2009, Hovione announced its plans to move to large-scale
manufacture of its TwinCaps inhaler, following its use in Phase III
trials of Daiichi Sankyo/Biota's long-acting neuraminidase inhibitor,
laninamivir (CS-8958). Daiichi Sankyo and Biota have a worldwide licence
to use TwinCaps for the treatment and prevention of influenza infections
and it is available for licensing in other indications, according to
Hovione.
Key Topics Covered:
-
Executive Summary
-
SWOT Analysis
-
Pharmaceutical Business Environment Ratings
-
Portugal - Market Summary
-
Regulatory Regime
-
Industry Trends And Developments
-
Industry Forecast Scenario
-
Competitive Landscape
-
Company Profiles
-
Table: Pharmaceutical Business Environment Indicators
Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/5417ca/portugal-pharmaceu.
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Source: Research and Markets
|
